Schmidt and colleagues reported inferior OS in Dutch ER-positive BC patients with BRCA2 mutations (HR = 2.04 95% CI 1.22–3.39) but not BRCA1 mutations [13]. This evidence concerns the gene BRCA2 and breast cancer.